|
|
|
|
 |
| Summary Description |
| Developing novel, localized anti-cancer therapies to avert side-effects |
|
| Management |
| Punit Dhillon, President and CEO;
Caryn Peterson,
Vice President, Regulatory Affairs; Brian McCluskey B.S. EE, Executive Director, Engineering; Veronica Vallejo, CPA, Vice President Finance and Controller;
Ernest Kitt,
Executive Director, Clinical Operations; Michael Cross, Ph.D.,
Chief Business Officer |
| |
|
|
|
|
|
|
|
|
|
|
|
| Description |
|
OncoSec Medical is developing novel, localized therapies against solid tumors to overcome side effects associated with non-targeted approaches. Contemporary non-targeted approaches include surgery, which carries the potential of physical disfigurement and/or debilitated organ function; radiation therapy, which can be very damaging to nerves, blood vessels, and organs within the target zone; and chemotherapy, which kills healthy as well as cancerous cells system-wide. OncoSec’s solid tumor therapies consist of an agent capable of selectively killing cancerous cells, coupled with a delivery system. The OncoSec Medical System (OMS) utilizes electroporation, which entails applying a brief electric field to a living cell in order to generate a transient increase in permeability in the cell’s outer membrane; this allows an agent previously injected into the area to flow into targeted cells by an increased factor of 1000 or more, while minimizing any impact on normal tissues. OMS ElectroChemotherapy has been demonstrated through data from Phases 1 through 4 to be safe and highly effective in eradicating solid tumors, including head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, and liver and pancreatic cancers. This later-stage biotechnology Company is also developing OMS ElectroImmunotherapy to deliver pro-inflammatory cytokine proteins into the body. |
|
| Technology / Differentiation |
| OncoSec's novel solid tumor therapies consist of two main components: the first is an agent capable of selectively killing cancerous cells or stimulating the immune system to kill cancerous cells; the second is a novel delivery system for the agent.
OncoSec's proprietary delivery system, called the OncoSec Medical System? (OMS), directly addresses this challenge of delivering the agent in a safe and effective manner by harnessing a scientific phenomenon known as electroporation, which involves applying a brief electric field to a living cell in order to render a transient increase in permeability, or pores, in the cell's outer membrane.
OncoSec's ElectroImmunotherapy program uses the OncoSec Medical System (OMS) to deliver engineered DNA plasmid constructs that encode a specific cytokine. Cytokines play a vital role in regulating the body's immune system against bacteria, viruses and cancer cells. However, in the case of a cancerous tumor, the cancer cells have adapted systems to evade the anti-tumor processes regulated by cytokines. The OMS ElectroImmunotherapy treatment approach is intended to boost the patients immune system and re-estabilish the effectiveness of the anti-tumor processes regulated by cytokines, which results in a selective and potent treatment effect. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members